WO2004111069A2 - Compose de saponine, solution de saponine renfermant celui-ci, procede de preparation de celui-ci, compositions pharmaceutiques, aliments sains et produits cosmetiques renfermant la saponine comme principe actif - Google Patents

Compose de saponine, solution de saponine renfermant celui-ci, procede de preparation de celui-ci, compositions pharmaceutiques, aliments sains et produits cosmetiques renfermant la saponine comme principe actif Download PDF

Info

Publication number
WO2004111069A2
WO2004111069A2 PCT/KR2004/001459 KR2004001459W WO2004111069A2 WO 2004111069 A2 WO2004111069 A2 WO 2004111069A2 KR 2004001459 W KR2004001459 W KR 2004001459W WO 2004111069 A2 WO2004111069 A2 WO 2004111069A2
Authority
WO
WIPO (PCT)
Prior art keywords
saponin
edible
group
ginseng
composition liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2004/001459
Other languages
English (en)
Inventor
Jang Youn Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2004111069A2 publication Critical patent/WO2004111069A2/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Definitions

  • the present invention relates to a novel saponin compound, a saponin composition liquid containing the same, a preparation method thereof, and a pharmaceutical composition, functional food and cosmetic product containing the saponin compound or the saponin composition as an active ingredient.
  • ginseng has been widely known as a representative nutritive tonic agent.
  • ingredients and pharmacological activities of ginseng that have been known up to now include anti-aging, anti-arteriosclerosis, treatment of hyperlipidemia, treatment of hepatic insufficiency, improvement of liver function, protection from radiation injury, immune enhancement, improvement of cerebral function, antithrombotic, anti-stress, anti-diabetic, anti-hypertensive, anti-tumor effects, etc.
  • research into such various pharmacological effects has focused on studies of ginseng extracts, specifically saponins that have been known to play a key role in exhibiting the efficacy of ginseng.
  • Saponin components of ginseng are largely classified into three groups according to chemical structure: protopanaxadiol (PD); protopanaxatriol (PT); and oleanolic acid.
  • Saponin existing on the plant system is a family of oleanane saponin, while ginseng saponin is dammarane-family triterpenoid saponin that is not isolated from the plant system.
  • Ginseng saponins were found to be completely different from those found in other kinds of plants, thus they are called ginsenoside, meaning ginseng glycoside, so that they can be distinguished from other plant saponins.
  • ginseng saponin components contained in ginseng in a large quantity include dammarane-family triterpenoid diols or triols.
  • main components of ginseng saponin include three benzene rings, cyclopentane, sugar moieties (glycon) and more than 450 kinds of non-sugar moieties (aglycon).
  • the inventor has reached findings that the novel saponin composition liquid has enhanced therapeutic effects of dermal eczema, tinea pedis, allergic dermatitis or atopic dermatitis, and treatment of other various diseases occurring to skin, eye, nose, mouth, tongue, pharynx, larynx, etc. as well as the same pharmacological efficacy as that of the conventional saponin composition liquid, finally completing the present invention.
  • FIG. 1 is a spectral diagram showing High Performance Liquid Chromatograph (HPLC) analysis of a composition liquid according to the present invention
  • FIG. 2 is a spectral diagram showing HLPC analysis of a composition prepared by Keumsan Ginseng Association of Korea.
  • FIG. 3 a spectral diagram showing HLPC analysis of a composition of a Cheongkwanjang product that is Korean red ginseng prepared by KT&G Corporation.
  • the present invention provides a novel saponin compound having the formula:
  • radicals R 2 6 ⁇ R29, R'4, R' ⁇ and R'io represent hydrogen atom, or a glycon of monosaccharides, disaccharides, oligosaccharides or polysaccharides, a glycon of monosaccharides, disaccharides, oligosaccharides or polysaccharides may be optionally bonded to a carbon[C] on a double bond of the hexagonal ring or the pentagonal ring, and wherein at least one selected from the group consisting of the following groups is induced by an addition reaction into the radicals R 26 ⁇ R2 9 , R4, R f 9 and R' 10 or a carbon atom on a double bond of the hexagonal ring or the heptagonal ring: a group of edible organic acids containing 1 to 20 carboxyl groups; a group of flavonoids having a backbone containing three phenyl groups contained in edible propolis;
  • novel saponin compound according to the present invention has a variety of chemical structures according to the position where the addition reaction occurs.
  • novel saponin compound and a saponin composition liquid comprising the novel saponin compound are prepared in the following manner.
  • the above formula can be simply explained based on the Onewholeness Theory, as proposed by the inventor of the present invention, the data of which is available upon request.
  • Ginseng is immersed in a sweet drink made from rice or a residual liquid produced in the previous preparation process of the saponin composition liquid for 10 minutes to 1 hour, and aged in a closed vessel. That is, the ginseng or dried ginseng of either stem or leaf is aged at a temperature of 40 to 60 0 C for 7 to 21 days, and fresh ginseng is aged at a temperature of 20 to 50 0 C for 1 to 7 days. The aging may cause degeneration of alkaloid compounds on the epidermis of the ginseng. 2) Sugar addition step
  • the pretreated ginseng was injected into an extraction reactor with a reflux device together with saccharides, edible organic acids, edible salts, reaction catalysts and water, or optionally with edible sweeteners.
  • the reaction was maintained at 120 0 C, under atmospheric pressure for 20 hours or more, and the injected materials including ginseng is removed
  • the preheated ginseng is used in an amount of 1 to 30 wt%, preferably 5 to 25 wt%, based on the total weight of water used.
  • saccharide useful in the present invention examples include honey, monosaccharides, disaccharides, oligosaccharides, and polysaccharides.
  • the saccharide is used in an amount of 1 to 20 wt%, preferably 1.5 to 15 wt%.
  • polysaccharide examples include one selected from the group consisting of pulluran, amylose xyloglucans, amylopectin, dextran, cyclodextrin, mannans, hydroxyethyl dextrans, inulin, chitin, chitosans, and aqueous celluloses.
  • edible salt useful in the present invention include a single substance or a mixture of two or more materials selected from the group consisting of bay salt, bamboo salt, mineral salt, and parched salt, and is used in an amount of 0.05 to 2 wt%, preferably 0.1 to 1 wt%.
  • reaction catalyst useful in the present invention include a single substance or a mixture of two or more materials selected from the group consisting of platinum, gold, silver, zinc, copper, selenium and elvan, and is used in an amount of 0.05 to 2 wt%, preferably 0.1 to 1 wt%.
  • Examples of the edible organic acid dried pharmaceutical agent useful in the present invention include a single substance or a mixture of two or more materials selected from the group consisting of formic acid, citric acid, succinic acid, maleic acid, acetic acid, alum, plum, Chinese quince, mugwort, motherwort, garlic extract, persimmon vinegar, and unhulled rice vinegar, and is used in an amount of 0.1 to 3 wt%, preferably 0.3 to 2 wt%.
  • Examples of the edible sweetener useful in the present invention include a single substance or a mixture of two or more materials selected from the group consisting of honey, royal jelly, monosaccharide, disaccharides, such as oligosaccharides, polysaccharide, black sugar, jujube, licorice, raisin, dried persimmon, arrow root, Schisandra chinensis, rubus schizostylu, comus officinalis, lycium chinense, cuscuta japonica, Rehmaniae radix preparata, poria cocos, ox bezoar, musk, powdered cervi cornus, cervi pantotrichum comu, bear gall, pig gall, and edible proteins including mushrooms.
  • the edible sweetener is used in an amount of 0.1 to 3 wt%, preferably 0.3 to 2 wt%.
  • Pure compounds of the formula I can be isolated by subjecting the saponin compounds to general purification and separation techniques, such as chromatography or extraction using an organic solvent.
  • the present invention provides a pharmaceutical composition and functional food containing the novel saponin compound of the formula I or a saponin composition liquid containing the saponin compound as an active ingredient.
  • the pharmaceutical composition and functional food have various pharmacological effects including immune enhancement, vitality enhancement, improvement of liver function, withdrawal of hangover, promotion of protein generation, promotion of cerebral activities and improvement of attention, activated recuperation of health after surgical operation, and prevention or treatment of diabetes, impaired blood circulation, depression, dermal inflammatory disease, dermal eczema, dermatophytosis, allergic rhinitis, and empyema, and promoting generation of protein effective in treatment and prevention of a bruise, a burn, bleeding internal diseases, and regeneration of protein in the cerebrum, medullar, or endothelium/exothelium.
  • the pharmaceutical composition and functional food have enhanced therapeutic effects of dermal eczema, tinea pedis, allergic dermatitis or atopic dermatitis, and treatment of other various diseases occurring to skin, eye, nose, mouth, tongue, pharynx, larynx, etc.
  • the novel saponin compound is preferably contained in an amount of not less than 0.01 wt%.
  • the pharmaceutical composition can be formulated in a variety of dosage forms, including oral administration, parenteral administration and topical administration.
  • the pharmaceutical composition can be formulated, in combination with a pharmaceutically acceptable carrier, into oral dosage forms including granules, capsules, solutions, or suspensions, injectables, suspensions, topical preparations including ointments, creams or solutions, suppositories, and other various dosage forms.
  • the carrier used in combination with the composition according to the present invention is a pharmaceutically acceptable carrier.
  • examples of the carrier include binders, humectants, disintegrating agents, adjuvants, solubilizers, dispersants, stabilizers, suspensions, coloring agents, or flavoring agents.
  • examples of the carrier include preservatives, pain relieving agents, solubilizers, or stabilizers.
  • examples of the carrier include basic matrixes, adjuvants, lubricants, or preservatives.
  • the thus prepared pharmaceutical formulations can be administered either orally or parenterally. Also, in order to prevent the drug from being dissolved in gastric acid during oral administration, an obstipatia can also be used.
  • solid formulations for oral administration e.g., granules
  • enteric-coated dosage form can be formulated in the enteric-coated dosage form.
  • Doses of the compositions according to the present invention may vary according to the formulation, and the desirable dose to be administered may be appropriately selected according to the absorption, inactivation rate and excretion speed of active ingredients, the age, sex and severity of a subject.
  • the saponin compound is preferably administered at a dose of 10 ⁇ 30 mg 1 ⁇ 3 times per day
  • the saponin composition liquid is preferably administered at a dose of 20 ⁇ 30 cc 1 ⁇ 3 times per day.
  • the present invention provides a cosmetic product comprising the novel saponin compound or the saponin composition liquid as an active ingredient.
  • the cosmetic product contains the novel saponin composition liquid as the active ingredient, the novel saponin composition liquid is preferably contained in an amount of 30 - 90 wt% based on the total weight of the composition.
  • the cosmetic product of the present invention may include 5-25 wt% of edible ethyl alcohol, 0.5 ⁇ 5 wt% of a herbal extract, and 0.1-50 wt%, preferably 0.5-35 wt%, of a general additive.
  • the herbal extract is one or more edible vegetable extracts selected from the group consisting of cucumber, sponge goard, aloe and cordyceps extracts, and one or more additives selected from the group consisting of bush mushroom, agaric mushroom, bus mushroom, topspin mushroom, Reishi mushroom, oak mushroom, cordyceps sinensis, Angelicae gigantis radix, rehmannia glutinosa, white poria cocos, ox bezoar, musk, cervi cornus powder, cervi pantotrichum cornu, bear gall, and pig gall.
  • the general additive is one or more selected from the group consisting of one or more honey wax, paraffin oil, shark liver oil, caviar, pectins.
  • the cosmetic product according to the present invention can be formulated in the form of skin lotion, moisturizing lotion, or creams.
  • the cosmetic product according to the present invention may be formulated in the form of a skin-cleansing agent, a hair care agent, shower and baths preparations, make-up cosmetics and skin care cosmetics.
  • Ginseng was first pretreated by immersing the same in a residual liquid produced in the previous preparation process of a saponin composition liquid for 60 minutes, and aging the resultant ginseng at a temperature of about 25 0 C for one day.
  • the reaction catalyst was injected into a lower portion of the extraction reactor, the saccharide, the bamboo salt and the organic acid were dissolved in water and the ginseng and the dried pharmaceutical agents were injected into an upper portion of the extraction reactor, causing a reaction for approximately 40 hours at approximately 120 0 C under atmospheric pressure for extraction. Then, solid matters such as ginseng were filtered for removal and evaporated under reduced pressure for removal of water, yielding not greater than 3000 g of the extract, thereby obtaining a saponin composition liquid containing saponin compounds of the formula I.
  • Preparation Example 2 Saponin composition liquid Ginseng was first pretreated by immersing the same in a residual liquid produced in the previous preparation process of a saponin composition liquid for 30 minutes and aging the resultant ginseng at a temperature of about 30 0 C for two days.
  • Preparation Example 3 Saponin composition liquid Ginseng was first pretreated by immersing the same in a residual liquid produced in the previous preparation process of a saponin composition liquid for 20 minutes, and aging the resultant ginseng at a temperature of about 27 0 C for 5 days.
  • Preparation Example 4 saponin composition liquid Ginseng was first pretreated by immersing the same in a residual liquid produced in the previous preparation process of a saponin composition liquid for 40 minutes, and aging the resultant ginseng at a temperature of about 25 0 C for 10 days.
  • 300 g of the pretreated ginseng 100 g of a combination containing 80 g of honey, 10 g of glucose and 10 g of millet jelly, 40 g of an edible sweetener consisting of 20 g of jujube, 10 g of boiled rehmannia glutinosa, 5 g of licorice and 5 g of dried persimmon, 20 g of an edible organic acid consisting of 19 g of plum and 1 g of citric acid, 1.5 g of bamboo salt, a reaction catalyst consisting of 19 g of elvan and 1 g of platinum sand, and 3000 g of water, were separately injected into an extraction reactor provided with a reflux device.
  • Preparation Example 5 Saponin composition liquid Ginseng was first pretreated by immersing the same in a residual liquid produced in the previous preparation process of a saponin composition liquid for 15 minutes, and aging the resultant ginseng at a temperature of about 32 ° C for one day.
  • the pretreated ginseng 150 g of a combination containing 100 g of honey and 50 g of millet jelly, 30 g of an edible sweetener consisting of 25 g of jujube, 2 g of licorice and 3 g of boiled rehmannia glutinosa, 5 g of licorice and 5 g of dried persimmon, 40 g of an edible organic acid consisting of 20 g of plum, 10 g of Chinese quince, 5 g of cider vinegar and 5 g of unhulled rice vinegar, 2 g of bamboo salt, a reaction catalyst consisting of 5 g of pellet-type silver and 25 g of elvan, and 3000 g of water, were separately injected into an extraction reactor provided with a reflux device.
  • an edible sweetener consisting of 25 g of jujube, 2 g of licorice and 3 g of boiled rehmannia glutinosa, 5 g of licorice and 5 g of dried
  • a skin lotion having the following composition was prepared using the saponin composition liquid prepared in Preparation Example 1 : Saponin composition liquid 60 wt%
  • a moisturizing lotion having the following composition was prepared using the saponin composition liquid prepared in Preparation Example 1 : Saponin composition liquid 70 wt%
  • the peaks detected from the compound according to the present invention were greater than or equal to 9 mV.
  • the peak exhibited by the compound 2 is not detectable from the conventional red ginseng and a gentle peak of 2.5 mV was observed.
  • the peak exhibited by the compound according to the present invention has a gentle profile around 100 minutes, which is completely new compared to the conventional case, suggesting that the new peak is exhibited by the novel compound prepared in the present invention.
  • Tables 1 and 2 show the results illustrated in FIGS. 1 and 2.
  • the contents of the saponin components according to the present invention are measured using data shown in Table 1 , and the measurement results are shown in Table 3.
  • Table 1 The contents of the saponin components according to the present invention are measured using data shown in Table 1 , and the measurement results are shown in Table 3.
  • Clinical test example 1 Age: 55 (Male) Symptoms: Hand eczema, dermatophytosis
  • Preparation Example 1 was applied to a subject having eczema sites on hand and foot three times daily over a period of 3 to 10 days. The result showed that the skin became softened and bright-complexioned without inducing any symptoms of the eczema.
  • Preparation Example 3 was administered twice over a period of 90 days. Thereafter, vitality was recovered and chronic fatigue was cured while the attention was improved. Also, unusually dark and rough skin was whitened and softened.
  • Preparation Example 4 was diluted in 1 cup of water and administered once or twice daily over a period of 100 days. After administration of the diluted saponin composition liquid, the state of depression was overcome, the vitality was recovered and the fatigue was cured. The dark-yellow, coarse skin became whitened, softened and bright-complexioned.
  • Symptoms Pneumonic symptoms, weakened immunity Result: 5 cc of the saponin composition liquid prepared in Preparation Example 5 was administered twice daily over a period of 2 weeks. After administration of the saponin composition liquid, the vitality was recovered and the fatigue was cured. The dark-yellow, coarse skin became whitened and softened.
  • Symptoms Common cold and complications due to weakened immunity Result: After administration of 20 cc of the saponin composition liquid prepared in Preparation Example 2 once daily over a period of 60 days, the immunity was fortified and the vitality was recovered, so that cold complications were withdrawn from the subject without suffering from the cold.
  • Symptoms Symptoms occurring during the period of convalescence after gastrotomy
  • Clinical test example 10 Age: 50 (Female) Symptoms: Crural bloat due to impaired blood circulation and diabetic symptoms
  • Symptoms Diabetes, cold and bacterial complications Result: After administration of 25 cc of the saponin composition liquid prepared in Preparation Example 2 twice daily over a period of 40 days, the immunity for bacterial diseases was fortified and the vitality was recovered, so that various complications were withdrawn. Also, fortified metabolism of carbohydrates noticeably lowered the glucose level.
  • Skin lotion and moisturizing lotion prepared in Preparation Examples 6 and 7 were continuously applied to seven 22 to 42 old women who cannot use general cosmetic products due to their hypersensitive skin three times daily over a period of a week. As a result, no hypersensitive response and skin irritation occurred.
  • the pharmaceutical composition and functional food comprising a saponin compound or a saponin composition liquid containing the same as an active ingredient has various pharmacological effects, including immune enhancement, vitality enhancement, improvement of liver function, withdrawal of hangover, promotion of protein generation, promotion of cerebral activities and improvement of attention, activated recuperation of health after surgical operation, and prevention or treatment of diabetes, impaired blood circulation, depression, dermal inflammatory disease, dermal eczema, dermatophytosis, allergic rhinitis, empyema, and so on.
  • the cosmetic product comprising the saponin compound or a saponin composition liquid containing the saponin compound can also be suitably applied to the person who has sensitive skin.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

art.17(2)
PCT/KR2004/001459 2003-06-19 2004-06-18 Compose de saponine, solution de saponine renfermant celui-ci, procede de preparation de celui-ci, compositions pharmaceutiques, aliments sains et produits cosmetiques renfermant la saponine comme principe actif Ceased WO2004111069A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20030039622 2003-06-19
KR10-2003-0039622 2003-06-19
KR10-2003-0053378 2003-08-01
KR20030053378 2003-08-01

Publications (1)

Publication Number Publication Date
WO2004111069A2 true WO2004111069A2 (fr) 2004-12-23

Family

ID=33554578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2004/001459 Ceased WO2004111069A2 (fr) 2003-06-19 2004-06-18 Compose de saponine, solution de saponine renfermant celui-ci, procede de preparation de celui-ci, compositions pharmaceutiques, aliments sains et produits cosmetiques renfermant la saponine comme principe actif

Country Status (2)

Country Link
KR (1) KR100746799B1 (fr)
WO (1) WO2004111069A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006223140A (ja) * 2005-02-16 2006-08-31 Kiyoshi Sato 栄養補助食品
GB2455585A (en) * 2008-01-16 2009-06-17 Ali Reza Rezai-Fard Composition for treating a skin disorder
US7981308B2 (en) 2007-12-31 2011-07-19 Robert Bosch Gmbh Method of etching a device using a hard mask and etch stop layer
CN103613680A (zh) * 2013-12-05 2014-03-05 三峡大学 一种醇沉竹节参多糖及其制备方法与它的用途
CN104383028A (zh) * 2014-10-30 2015-03-04 洛阳蓝斯利科技有限公司 一种甘草足浴粉的制备方法
CN114957495A (zh) * 2022-01-04 2022-08-30 北华大学 五味子植物多糖及其制备方法和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101106499B1 (ko) * 2009-03-24 2012-01-20 장흥군 헛개나무 어린가지 추출물을 포함하는 간보호 효과용 식품 조성물
KR101155967B1 (ko) * 2009-09-11 2012-06-18 김달수 게르마늄, 맥반석 및 홍삼 추출물을 함유하는 알레르기성 비염의 예방 및 치료용 건강식품조성물
KR101947595B1 (ko) * 2011-09-30 2019-02-15 (주)아모레퍼시픽 차나무 뿌리 유래 사포닌을 함유하는 계면활성제 및 이를 포함하는 세정제 조성물
KR101380556B1 (ko) * 2012-04-26 2014-04-01 합자회사 에스에이치해양수산개발 해삼 유래 사포닌 함유 소금을 포함하는 비누조성물 및 이의 제조방법
KR101998562B1 (ko) * 2016-10-06 2019-07-10 농업회사법인 월파 주식회사 홍삼 식혜 제조방법
KR102247551B1 (ko) * 2020-12-31 2021-05-03 주식회사 네이처프롬 인삼수를 활용하여 붓기를 완화할 수 있는 크림 및 이를 제조하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930005989B1 (ko) * 1991-01-22 1993-07-01 주식회사 대웅제약 인삼 사포닌의 제조방법
KR0169536B1 (ko) * 1996-02-27 1999-01-15 손경식 신규한 인삼 사포닌, 그의 제조방법 및 이를 유효성분으로 하는 항종양제

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006223140A (ja) * 2005-02-16 2006-08-31 Kiyoshi Sato 栄養補助食品
US7981308B2 (en) 2007-12-31 2011-07-19 Robert Bosch Gmbh Method of etching a device using a hard mask and etch stop layer
US8232143B2 (en) 2007-12-31 2012-07-31 Robert Bosch Gmbh Device formed using a hard mask and etch stop layer
GB2455585A (en) * 2008-01-16 2009-06-17 Ali Reza Rezai-Fard Composition for treating a skin disorder
GB2455585B (en) * 2008-01-16 2010-07-28 Ali Reza Rezai-Fard Capsicum seeds for the treatment of eczema and dermatitis
CN103613680A (zh) * 2013-12-05 2014-03-05 三峡大学 一种醇沉竹节参多糖及其制备方法与它的用途
CN103613680B (zh) * 2013-12-05 2016-06-01 三峡大学 一种醇沉竹节参多糖及其制备方法与它的用途
CN104383028A (zh) * 2014-10-30 2015-03-04 洛阳蓝斯利科技有限公司 一种甘草足浴粉的制备方法
CN114957495A (zh) * 2022-01-04 2022-08-30 北华大学 五味子植物多糖及其制备方法和应用

Also Published As

Publication number Publication date
KR100746799B1 (ko) 2007-08-23
KR20060038396A (ko) 2006-05-03

Similar Documents

Publication Publication Date Title
CN100534474C (zh) 一种具有增强免疫功效的组合物及其制备方法和其用途
DE3328262A1 (de) Arzneimittelzubereitung zur besserung von krebssymptomen
WO2004111069A2 (fr) Compose de saponine, solution de saponine renfermant celui-ci, procede de preparation de celui-ci, compositions pharmaceutiques, aliments sains et produits cosmetiques renfermant la saponine comme principe actif
CN103168883A (zh) 可增强免疫力、抗病原微生物、抗病毒的茶饮料颗粒剂及其制备方法
JP2008231031A (ja) デヒドロエピアンドロステロン産生促進剤およびその用途
KR100635025B1 (ko) 식초를 이용한 인삼 제제 및 이의 제조방법
CN112190593A (zh) 一种抑制trpv1通路的多糖组合物及其制备方法和应用
CN111329907A (zh) 一种具有抗缺氧功能的芫根组合物及其制备方法和应用
KR101416671B1 (ko) 초음파 처리를 이용한 인삼 프로사포게닌 고농도 함유 인삼 잎 및 줄기 제제 및 이의 제조방법
CN101744986B (zh) 人参、麦冬、五味子的单独提取方法及其制剂
KR20030080296A (ko) 인삼으로부터 분리된 사포닌 분획 및 유도체를 함유하는알러지 질환의 예방 및 치료를 위한 조성물
CN101744991B (zh) 一种人参、麦冬、五味子的单独提取方法及其制剂
KR101416669B1 (ko) 초음파 처리를 이용한 인삼 프로사포게인 고농도 함유 인삼 열매 제제 및 이의 제조방법
CN101744997B (zh) 一种人参、麦冬、五味子的提取方法及其制剂
CN101745014B (zh) 人参、麦冬和五味子的提取方法及其制剂
CN101745016B (zh) 一种"人参,麦冬和五味子"的提取方法及其制剂
CN101745012B (zh) 一种人参/麦冬和五味子的提取方法及其制剂
CN101745017B (zh) 一种人参、麦冬以及五味子的提取方法及其制剂
CN101745011B (zh) 一种人参、麦冬和五味子的提取方法及其制剂
KR20010009653A (ko) 성기능 장애를 위한 치료용 조성물
CN107595870B (zh) 一种健脑安神的药物组合物、药物制剂及应用和制备方法
CN1814214A (zh) 一种治疗体形消瘦、体质虚弱的中药组合物及其制备方法
JP2014155489A (ja) サルトリイバラ葉抽出物を含有する糖尿予防及び治療用の組成物
CN101745000B (zh) 一种人参,麦冬和五味子的提取方法及其制剂
CN113521186B (zh) 一种降血糖药物及其制备方法和应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020057024035

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020057024035

Country of ref document: KR

122 Ep: pct application non-entry in european phase